KALEXSYN AT A GLANCE

Over the last ten years we have continued to differentiate ourselves from our competitors by our ability to solve complex synthetic problems and deliver complex molecular targets. We bring our unique expertise to provide hypothesis-driven medicinal chemistry and excellent ROI through our efficiency and productivity in meeting our customers’ goals. Kalexsyn has been able to attract and retain top scientific talent, provide excellent in-house analytical services, offer efficiencies through the use of Symyx's electronic notebook, and provide creative process route improvement in state of the art laboratories. We serve a global customer base of pharmaceutical and biotechnology companies. Our scientists average 15 years experience in practicing the art of chemistry and bring both a breadth and depth of chemistry knowledge to our clients.

Kalexsyn was founded in 2003 following the closure of Discovery Research operations at Pharmacia in Kalamazoo. Kalexsyn’s co-founders, Dr. Robert Gadwood and David Zimmermann worked with numerous contract research organizations to provide synthetic chemistry support while at Pharmacia. Their experiences in working with CROs allowed them to identify weaknesses in the practices of many CROs and create a unique company to address the needs of the pharmaceutical and biotechnology community.

Key Personnel


David Zimmermann, CEO


Mr. Zimmermann has worked in the life science industry for over a quarter century. Following a 23 year career at The Upjohn Company, Pharmacia and Upjohn, and Pharmacia he co-founded Kalexsyn, Inc. where he has served as Chief Executive Officer. Under his leadership, Kalexsyn has maintained a steady and rapid growth in a challenging economic environment. Revenue growth for Kalexsyn has far outpaced expectations with the successful partnering of Kalexsyn with companies both in the US and in Europe. Kalexsyn provides early drug discovery lead optimization services to pharmaceutical and biotechnology partners. While at Pharmacia, Zimmermann was responsible for negotiations and management of outsourcing contracts, managing an operating and capital budget of $16.4 million annually as well as maintaining leadership roles on therapeutic program teams in both the infectious disease and CNS areas.

Dr. Robert Gadwood, President & CSO


In 2003, Dr. Gadwood conceived of Kalexsyn in response to the closure of Pharmacia human health research in Kalamazoo. He co-founded Kalexsyn with Mr. David Zimmermann and serves as its President and Chief Scientific Officer. Dr. Gadwood oversees all scientific, financial, and organizational aspects of Kalexsyn. Under his leadership Kalexsyn has enjoyed steady growth over the last ten years. In 2010 Dr. Gadwood was named Entrepreneur of the year by Ernst and Young for the state of Michigan. Dr. Gadwood received a BS in chemistry from Marquette University in 1974 and a PhD in Organic Chemistry from the University of Wisconsin in 1978. After postdoctoral research at the University of Pittsburgh, Dr. Gadwood joined the faculty of Northwestern University as an Assistant Professor of Chemistry in 1980. In 1986, Dr. Gadwood joined the Upjohn Company in Kalamazoo, Michigan. During his distinguished career Bob worked in several therapeutic areas. He led the chemistry effort on the oxazolidinone program team that identified potential second generation anti-bacterial compounds (follow-up to Zyvox). He also led the Hair Growth program team that identified second generation hair growth stimulants (follow-up to Rogaine).

Dr. Brian Eklov, Director of Chemistry


Dr. Eklov joined Kalexsyn in 2007 as a research scientist. In 2012 he was promoted to Associate Director of Chemistry, and in 2016 he was promoted to his current position as Director of Chemistry. Dr. Eklov received his BS in chemistry from the University of Michigan in 1998. He went on to receive his Ph.D. in 2005 with Prof. Tom Hoye at the University of Minnesota. His studies focused on natural product structural assignment and synthesis, and the development of No-D NMR spectroscopy. Dr. Eklov’s post-doc work with Prof. Scott Denmark at the University of Illinois centered around elucidating the mechanism of the Lewis base catalyzed tetrachlorosilane mediated aldol reaction by Rapid-Injection NMR kinetic analysis. Dr. Eklov has served as chairman of the Kalamazoo local section of the ACS from 2014-2016, as program co-chair of the Joint Great Lakes/Central Regional ACS Meeting in 2015, and currently serves as an Adjunct Professor of Chemistry at Western Michigan University. 

Dr. Matthew Bedore, Associate Director of Chemistry


Dr. Bedore began his industrial career as a scientist at Kalexsyn in 2010 and was promoted to Associate Director of Chemistry in 2016. After receiving a B.S. in chemistry from Miami University in 2003 he attended The Ohio State University for his graduate work. Under the supervision of Prof. Leo Paquette he studied natural product synthesis focusing on the construction of Amphidinol 3, a dinoflagellate derived polyketide with potent antifungal and hemolytic activities. Upon receiving his Ph.D. in 2008, Dr. Bedore moved to the Massachusetts Institute of Technology where he began postdoctoral work with Prof. Tim Jamison. In his time at MIT, he expanded the emerging field of flow chemistry developing efficient processes for beta-amino alcohol formation, glycosylation of nucleosides, and photochemical deoxygenations in flow. Since his arrival at Kalexsyn, Dr. Bedore has worked on a broad range of projects spanning carbohydrate, steroid, medicinal, and early process development chemistry.

Ms. Rebecca Gross, Director of Operations


Ms. Gross joined Kalexsyn as a scientist in 2004. In 2007 she was promoted to Operations Manager where she assumed responsibility for all day to day operations at Kalexsyn, including Human Resources, employee benefits, and overseeing Kalexsyn’s environmental, health and safety program. In 2016 she was promoted to Director of Operations. Under her leadership Kalexsyn has developed and maintained an outstanding record of safety, keeping foremost the safety of Kalexsyn’s employees and protection of the environment. Prior to Kalexsyn, Ms. Gross was a research chemist at Pharmacia. In 1998, she earned a BS with a dual major in Chemistry and Biology from Alma College and is currently a Certified Hazardous Materials Manager (CHMM).

Our Vision
1
Chemistry Excellence Our scientists have practiced the art of medicinal and process chemistry for decades.
2
Problem Solving Our scientists have the experience to solve your complex synthetic problems.
3

Communication Our scientists understand that effective and timely communication are paramount.

Our Mission

"The mission of Kalexsyn is to provide unmatched chemistry services to our customers. We are a difference maker."

David Zimmermann, CEO